Wednesday 3 March 2010

Losartan (Cozaar) and Losartan + HCTZ (Hyzaar): Teva won 180 days exclusivity

Generic player Teva has won 180 days exclusivity for Losartan (Cozaar) and Losartan + HCTZ (Hyzaar) after Court of Appeals for District of Columbia Circuit overturned a lower court's decision that Teva had forfeited its exclusivity rights in the light of delisting of another Orange Book patent on polymorph by innovator Merck & patent assignee Du Pont.


The product patent on Losartan (Cozaar) and Losartan + HCTZ (Hyzaar) will expire on Apr 06, 2010. Now, other generic players will be able to launch this product after the expiry of Teva's 180 days exclusivity in Oct, 2010.

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker